Navigation Links
Biocartis Raises EUR10 Million in Series A Financing Round

LAUSANNE, Switzerland, October 15 /PRNewswire/ -- Biocartis SA, a diagnostics company focused on fast and low-cost, integrated molecular and immunodiagnostics based on its proprietary micro-technology platform, today announced the successful closing of a Series A equity financing round. The Company raised EUR 10 million (~ USD 14.9 million) from a syndicate of leading life science investors.

The deal was led by Aescap Venture (Amsterdam, The Netherlands). Other members of the syndicate are Biovest (Belgium), KBC Private Equity (Belgium), Advent Venture Partners (United Kingdom), and existing shareholder Benaruca (Luxemburg). Dinko Valerio for Aescap Venture, Rudi Marien for Biovest, Ruth Devenyns for KBC Private Equity, Raj Parekh for Advent Venture Partners, Peter Verhaeghe for Benaruca and Rudi Pauwels constitute the Board of Directors of Biocartis.

Biocartis has developed and licensed a series of new technologies to build a broadly applicable diagnostics platform for low to highly multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. The company will use the proceeds to develop a commercial version of its proprietary platform and first prototype assays.

"Biocartis has all the key ingredients necessary to become a world leader in diagnostics. It has groundbreaking new technology created with a clear vision of the end-product and the market in mind, exceptional management with a successful serial entrepreneur and an experienced and energetic team. This has now been complemented by a group of investors with highly relevant expertise in the various aspects required to build world class companies. We are delighted to be part of the team working towards the fulfillment of the great promise embedded in Biocartis," said Dinko Valerio, General Partner from lead investor Aescap Venture.

Rudi Pauwels, founder of Biocartis, Director and CEO, commented "This successful financing is an important endorsement of the innovation and advances the Biocartis team has made and allows us to further accelerate the development, validation and industrialization of the new diagnostic platform and its various components. I am particularly pleased that we are joined and backed by life-science investors who have had a very strong track record in building and financing some of the most successful European biotech and diagnostic companies."

Biocartis is based in Lausanne, Switzerland, where it benefits from access to the Swiss Federal Institute of Technology (Ecole Polytechnique Federale de Lausanne - EPFL), a leading European academic institution in Micro-&Nanotechnology and Life Sciences, with first-class clean room and laboratory facilities that can be accessed by the companies located in the EPFL Science Park. Access to this multi-disciplinary environment has already been crucial to Biocartis' rapid progress and will play an important role in its future development.

Note for the editor

About Biocartis -

Biocartis S.A. was founded in 2007 by Dr. Rudi Pauwels (Co-founder of Tibotec, Virco and Galapagos Genomics), Prof. Philippe Renaud (Prof. at EPFL), and Nader Donzel (Co-founder of Scitec laboratory Automation). Biocartis engages in the development of a novel diagnostics technology platform for low to highly multiplexed detection of bio-analytes. The Company is focused on delivering a versatile compact diagnostics platform, for use in various in vitro diagnostic settings that will drastically reduce the time and costs per value added data point.

About Aescap Venture -

Aescap Venture is a venture capital company investing in private medical companies in Europe. Aescap's Partners have a proven track record of success and the skills to coach entrepreneurs in accelerating the growth of their companies.

About Biovest - Rudi Marien

Rudi Marien was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories.

About KBC Private Equity -

The Life Sciences division of KBC Private Equity invests in early- to late-stage life-science companies, with a focus on pharmaceutical biotech. Investments include Ablynx, Devgen, Innogenetics, Movetis, and Tibotec-Virco.

About Advent Venture Partners -

Advent Venture Partners is a long established European Venture Capital firm with a strong record of building successful companies.

    For further information, please contact:
    Rudi Pauwels
    Phone: +41-21-693-90-51
    Fax: +41-21-560-42-91

SOURCE Biocartis

SOURCE Biocartis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
Post Your Comments:
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology:
(Date:12/1/2015)... Wilmington, Delaware (PRWEB) , ... December 01, 2015 ... ... award winner at the 7th Annual 2015 Golden Bridge Business Awards under the ... is a zero capex web based sample management software that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... quantification and optimization of adjunctive imaging is the focus of numerous abstracts accepted ... meeting, November 29-December 4, 2015. Nine abstracts highlight the use of Volpara ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Excellence (BHCOE) today announced that the organization has awarded Education and Developmental Therapies ... a Distinguished Award. The award celebrates exceptional special needs providers that excel in ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
Breaking Medicine News(10 mins):